论文部分内容阅读
目的观察苯磺酸氨氯地平联合缬沙坦治疗高血压的临床疗效及不良反应情况。方法回顾性分析2009年10月至2011年10月我卫生站自收治的165例高血压患者,随机分为苯磺酸氨氯地平组(A组)、缬沙坦组(B组)及苯磺酸氨氯地平和缬沙坦联合用药组(C组)进行治疗,疗程均为2个月,比较3组的临床疗效及不良反应。结果疗效评价,联合用药C组显效率和总有效率为65.5%、90.9%,均显著高于A组(43.6%、67.3%)和B组(40.0%、69.1%),3组差异有统计学意义(P<0.05)。不良反应比较,A组总计发生不良反应11例次,占20%;B组总计发生不良反应9例次,占16.4%;C组总计发生不良反应4例次,占7.3%。3组比较差异有统计学意义(P<0.05)。结论苯磺酸氨氯地平联合缬沙坦治疗高血压能提高治疗效果,减少不良反应发生率,值得临床推广应用。
Objective To observe the clinical efficacy and adverse reactions of amlodipine besylate combined with valsartan in the treatment of hypertension. Methods A retrospective analysis of 165 hypertensive patients admitted to our health station from October 2009 to October 2011 were randomly divided into three groups: group A (amlodipine besylate), group B (valsartan) and group B Amlodipine and valsartan combined treatment group (C group) for treatment, treatment were 2 months, the clinical efficacy and adverse reactions in the three groups were compared. Results The curative effect evaluation showed that the markedly effective rate and total effective rate in group C were 65.5% and 90.9%, respectively, which were significantly higher than those in group A (43.6%, 67.3%) and group B (40.0%, 69.1%) Significance (P <0.05). There were 11 adverse reactions in group A, accounting for 20%. A total of 9 adverse reactions occurred in group B, accounting for 16.4%. A total of 4 adverse reactions occurred in group C, accounting for 7.3%. The difference between the three groups was statistically significant (P <0.05). Conclusion Amlodipine besylate combined with valsartan in the treatment of hypertension can improve the therapeutic effect and reduce the incidence of adverse reactions, which is worthy of clinical application.